Who Paid My Doc
An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20 B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy
ClinicalTrials.gov NCT02290951
Research payments
$2,090,137
Through program year 2019, $2,090,137 in research payments was reported against An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Monoclonal Antibody, in Patients With Cd20 B-Cell Malignancies Previously Treated With Cd20-Directed Antibody Therapy, across 33 payments, paid by Regeneron Pharmaceuticals, Inc..
- Paid by
- Regeneron Pharmaceuticals, Inc.
- ClinicalTrials.gov
- NCT02290951
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $2,090,137 | 33 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
5 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.